Last reviewed · How we verify
NCT03017690
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
trial in Gastroenteropancreatic Neuroendocrine Tumor in 22 participants. Completed in 30 May 2018.
30 May 2018
Quick facts
| Lead sponsor | Ipsen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 22 |
| Start date | 12 April 2017 |
| Primary completion | 30 May 2018 |
| Estimated completion | 30 May 2018 |
| Sites | 5 locations across United States |
Conditions studied
- Gastroenteropancreatic Neuroendocrine Tumor — all drugs for Gastroenteropancreatic Neuroendocrine Tumor →
Sponsor
Ipsen — full company profile →
Who can join
18 and older, any sex, with Gastroenteropancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
Zhang XB, Fan YB, Jing R, Getu MA, et al · · 2024 · cited 24× · PMID 38835066 · DOI 10.1186/s40779-024-00535-6 -
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P, McBride A, Ray D, Pulgar S, et al · · 2019 · cited 17× · PMID 30924737 · DOI 10.1177/1078155219839458 -
An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis.
Yan H, Zhang JL, Leung KT, Lo KW, et al · · 2023 · cited 8× · PMID 36765694 · DOI 10.3390/cancers15030736
Verify or expand the search:
- PubMed search for NCT03017690
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastroenteropancreatic Neuroendocrine Tumor
Currently open trials in the same condition.
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT06256705 — Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionucl · NA · recruiting
- NCT05636618 — Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors · Phase 1, PHASE2 · recruiting
- NCT04727723 — Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in · active not recruiting
- NCT06155318 — 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours · recruiting
Other Ipsen trials
Trials by the same sponsor.
- NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
- NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
- NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
- NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
- NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03017690 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ipsen
- Last refreshed: 21 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03017690.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing